drugset
drugset / Trial / NCT03979638

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

NCT03979638 ↗

Phase 2 Terminated 68 enrolled Bellus Health Inc. - a GSK company
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough

Timeline

Start
2019-07-10
Primary completion
2020-04-23
Completion
2020-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule 25 mg Oral
Subject Camlipixant Small molecule 50 mg Oral
Subject Camlipixant Small molecule 100 mg Oral
Subject Camlipixant Small molecule 200 mg Oral

Indications

No indication recorded.